Background: POEMS syndrome is a plasma cell disorder manifested by Polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal gammopathy and Skin changes. Pulmonary morbidity includes restriction, decreased diffusing capacity for carbon monoxide (DLCO), respiratory muscle weakness, abnormal imaging, and pulmonary hypertension. Autologous peripheral blood stem cell transplantation (aPBSCT) is an effective treatment for POEMS syndrome. It is unknown if aPBSCT improves pulmonary morbidity. We hypothesize pulmonary morbidity will improve following aPBSCT. Methods: Retrospective cohort study of POEMS syndrome aPBSCT recipients from 2000 to 2010. Demographic, pulmonary function test (PFT), echocardiogram, cytokine, and imaging data at baseline and after aPBSCT were abstracted. Pre-and post-transplant data were compared using Wilcoxon signed-rank and McNemar's tests. Results: 53 patients met criteria. Median improvements in forced expiratory volume in 1 s (FEV 1 ), forced vital capacity (FVC), and total lung capacity (TLC) after transplant were 180, 315 and 350 ml respectively (median follow-up of 1.1 years). DLCO, maximal inspiratory pressure (MIP), and maximal expiratory pressure (MEP) improved by a median of 11, 12.5 and 10% predicted respectively. RVSP and chest imaging also improved. Vascular endothelial growth factor and IL-6 decreased by a median of 334 and 2 pg/ml respectively. All comparisons were statistically significant. Longitudinal data demonstrated stability in FEV 1 , MEP, and TLC and continued improvement in FVC, MIP and DLCO on subsequent PFTs (median follow-up 26.5 months). Conclusion: Patients with POEMS syndrome treated with aPBSCT have significant improvement in PFTs, respiratory muscle strength, imaging, and post-transplant IL-6. The improvement in PFTs persists during long-term follow-up. ª
Introduction
POEMS syndrome is a plasma cell dyscrasia associated with significant pulmonary morbidity. Pulmonary manifestations are common including pulmonary restriction, decreased diffusing capacity of the lung for carbon monoxide (DLCO), respiratory muscle weakness and pulmonary hypertension [1, 2] . In addition cough, respiratory muscle weakness, and pulmonary hypertension are associated with decreased median survival in POEMS syndrome [1, 3] . Cardiorespiratory failure is the most common cause of death [4, 5] . Therefore POEMS syndrome is an important systemic disease to pulmonologists, cardiologists, and intensivists.
Autologous peripheral blood stem cell transplantation (aPBSCT) is an effective treatment for the plasma cell dyscrasia [6] . However, poor pulmonary function is often considered a relative contraindication to aPBSCT. Thus POEMS patients with pulmonary morbidity are at risk for exclusion from this effective treatment. Interestingly, improvement in PFTs has been reported in three patients following aPBSCT for POEMS syndrome [7] . In addition, POEMS syndrome-associated pulmonary hypertension has been reported to respond to treatment [8e10] . It is unknown if reversibility of pulmonary morbidity in POEMS syndrome patients is a consistent finding. Understanding whether POEMS syndrome associated-pulmonary hypertension and/or abnormal pulmonary function tests are reversible, or not, would assist clinicians weighing the risks and benefits of aPBSCT.
It is also unknown what causes pulmonary hypertension in POEMS syndrome. Cytokines such as vascular endothelial growth factor (VEGF) and interleukin-6 (IL-6) have been postulated to play a role in pulmonary hypertension in this disorder [11e13] . Interestingly, VEGF has been demonstrated to decrease following aPBSCT [6] . A careful examination of IL-6 pre-and post-aPBSCT would be helpful to refute or endorse the hypothesized association between POEMS-associated pulmonary hypertension and elevated cytokines.
In this retrospective cohort study, we compare preaPBSCT and post-aPBSCT pulmonary function, echocardiogram, imaging and cytokine data to investigate whether aPBSCT impacts pulmonary manifestations of POEMS syndrome and whether pulmonary hypertension is associated with cytokine elevation. Some of the results have been previously reported in an abstract form [14] . This manuscript represents a focused analysis of pulmonary morbidity in a previously described cohort. [6] .
Materials and methods

Patient selection
This is a single-center, retrospective cohort study of all research consenting patients with POEMS syndrome who underwent autologous peripheral blood stem cell transplantation (aPBSCT) between 01/01/2000 and 07/31/2010 at our institution. Six patients with POEMS syndrome who were followed after receiving aPBSCT elsewhere were excluded (due to lack of baseline and aPBSCT data). The study was approved by Institutional Review Board of Mayo Clinic (IRB 2469-03). POEMS syndrome was diagnosed according to established diagnostic criteria [4, 15] . In brief, a diagnosis of POEMS syndrome requires presence of 
Autologous stem cell practice
Adult patients considered for autologous stem cell transplant at our institution are generally expected to have an Eastern Cooperative Oncology Group (ECOG) performance status of 0e2, a left ventricular ejection fraction of >40%, a forced expiratory volume in 1 s (FEV 1 ) and DLCO >50% although exceptions occur on a case-by-case basis [16] . The ECOG performance status eligibility criterion was waived in these patients since many had reduced performance status due to severe peripheral neuropathy. Those patients with the worst PFTs received attenuated dose of melphalan conditioning pre-aPBSCT.
Data collection
Demographic data, presence of pre-existing lung or heart disease, smoking history, radiologic imaging, pulmonary function tests (PFT), echocardiogram (ECHO), weight, and laboratory values of IL-6 and VEGF were abstracted before and three or more months after transplant. When multiple values were available, the data immediately pre-transplant and the data closest to (but no earlier than) three months post-aPBSCT were used for the post-transplant data. A second post-aPBSCT PFT was abstracted if available before November 15, 2012.
Pulmonary function test
All pulmonary function tests were performed according to national practice guideline standards for repeatability and acceptability.
[17e20].
Echocardiography
All transthoracic echocardiographies were performed in accordance with national practice guidelines [21, 22] . The right ventricular systolic pressure (RVSP) was calculated using the tricuspid valve systolic regurgitant jet velocity. [23] .
Definitions
Smoking history was recorded as the number of years of smoking multiplied by the number of packs per day (pack years). Predicted normal values for PFTs were calculated using a standardized database [24, 25] 
Data analysis
Categorical variables were summarized with frequencies and percentages and continuous variables were summarized using medians and interquartile ranges (IQR). Data analysis was performed using Wilcoxon signed-rank and McNemar's tests where appropriate (JMP, version 8.0; SAS Institute Inc; Cary, NC). Any p-value less than 0.05 was considered statistical significant.
Results
Demographics
Patient characteristics are summarized in Table 1 . Fiftythree patients were included. Thirty-eight percent were current or former smokers with an average smoking history of 23.6 pack-years. One patient each had pre-existing chronic obstructive pulmonary disease, asthma or congestive heart failure. Twenty-nine percent of the patients with elevated baseline IL-6 (N Z 9/31) had Castleman disease.
Test measurements
Patients demonstrated statistically significant improvements in PFTs (other than residual volume), RVSP, and measured cytokines after aPBSCT (see Table 2 ). The median interval between the pulmonary function tests was 1.1 years with a narrow IQR of 0.9e1.2 years. The overall median value increased for FEV 1 (6% or 180 ml; N Z 38), FVC (6.5% or 315 ml; N Z 38), and TLC (5% or 350 ml; N Z 27). Similarly the median percent predicted increased for MIP (12.5%; N Z 30) and MEP (10%; N Z 29). RV/TLC was significantly smaller following aPBSCT (median decrease of 7%; N Z 27) consistent with the observed improvements in maximal respiratory pressures. However residual volume did not demonstrate a statistically significant difference (p Z 0.33; N Z 27) following aPBSCT suggesting the improvement in RV/TLC was secondary to the observed increases in the TLC. DLCO was able to be adjusted for hemoglobin in 96% of baseline and 81.7% of subsequent DLCO measurements limiting confounding by anemia. DLCO also significantly improved, although the median improvement was small (median of 11% or 2.6 gm/dL; N Z 38). The subset of patients abnormal at baseline demonstrated larger median improvements FVC (10% or 360 ml), TLC (8% or 540 ml), DLCO (15%), MIP (23%), MEP (15%), and RV/TLC (decrease of 12%) following aPBSCT ( Table 3) . The subset of patients with an abnormal RV at baseline was small; the abnormal RVs at baseline did not demonstrate significant improvement following aPBSCT. Although the number of patients with repeat ECHO was small, the RVSP likewise demonstrated small but significant improvement following transplant (median decrease of 7 mm Hg; N Z 13). In addition, the cytokines VEGF and IL-6 decreased post-aPBSCT by a median of 334 (N Z 31) and 2.04 pg/ml (N Z 18) respectively (see Table 2 ).
Longitudinal PFT data
A second post-aPBSCT PFT was abstracted if available before November 15, 2012 in order to determine if observed PFT changes were persistent and whether continued late improvement occurred (see Table 4 ). Thirtytwo patients had further pulmonary function test follow-up (median follow-up of 26.5 months with IQR 24e33 months). FEV 1 did not demonstrate significant change between initial post-aPBSCT and subsequent measure (p Z 0.076; N Z 32). Likewise subsequent TLC and MEP measurements did not demonstrate significant change (p Z 0.72; N Z 29 and p Z 0.08; N Z 27 respectively). This suggests observed initial improvements in FEV 1 , TLC and MEP are persistent but that further improvement does not occur. Interestingly, FVC demonstrated continued small but significant improvement with a median increase of 1.5% and IQR -1 to 5.75% (p Z 0.03; N Z 32). DLCO also continued to demonstrate small improvement on subsequent testing with a median improvement of 4% and IQR 0.25e11% (p Z 0.0006; N Z 32). MIP likewise continued to demonstrate significant improvement with a median increase of 6% predicted with IQR -8 to 19% (p Z 0.034; N Z 27). POEMS Z polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy and skin changes; IQR Z interquartile range; aPBSCT Z autologous peripheral blood stem cell transplantation; FEV 1 Z forced expiratory volume in 1 s; FVC Z forced vital capacity; TLC Z total lung capacity; DLCO Z diffusion capacity of the lung for carbon monoxide; MIP Z maximum inspiratory pressure; MEP Z maximum expiratory pressure; RV Z residual volume; RVSP Z right ventricular systolic pressure; VEGF Z vascular endothelial growth factor; IL-6 Z interleukin-6; Hb Z hemoglobin.
Respiratory failure and survival
Thirteen patients required an intensive care unit stay in the 90-day period following aPBSCT (median length of stay four days). Of these, five patients required vasopressor use. Five patients required intubation and mechanical ventilation (median duration of eleven days) and three of those patients required non-invasive positive pressure ventilator (median duration of five days). Patients with respiratory failure did not have other known pre-existing lung disease although two were smokers. All five had an abnormal DLCO at transplant (median 64% predicted). Median MIP and MEP were 67% and 51% predicted respectively; four out of five with respiratory failure had abnormal respiratory muscle function. Three patients had abnormal FEV 1 and FVC; median FEV 1 and FVC for those with respiratory failure were 67% and 73% predicted respectively. Only one patient had an abnormal TLC (median 90% predicted for respiratory failure subset). There was no association between respiratory failure and abnormal DLCO (p Z 0. There was one death 115 days after aPBSCT; cause of death was not determined.
Radiological changes
Patients had an improvement in radiologic abnormalities following aPBSCT (see example Fig. 1A and B) . Forty-seven percent of patients had an abnormal CXR prior to aPBSCT (N Z 51). Following aPBSCT, the number of patients with a normal CXR increased (p Z 0.02; N Z 39 patients with CXR) with a decrease in the number with infiltrates on CXR (p Z 0.002). Likewise the number of patients with normal chest CTs increased (p Z 0.008; N Z 21 imaged) with a decrease in the number of infiltrates on chest CT (p Z 0.02). Thirteen patients prior to transplant had 
Discussion
We are the first to demonstrate a statistically significant improvement in pulmonary function test data and RVSP in POEMS syndrome patients following aPBSCT. We are also the first to demonstrate lasting improvement in PFT measures over 2 years following aPBSCT.
Pulmonary function test
We previously demonstrated that pulmonary manifestations were common in patients with POEMS syndrome and included pulmonary hypertension, restrictive lung disease, respiratory muscle weakness, and an isolated decreased DLCO [1] . Prior preliminary evidence suggested that the PFT abnormalities may be reversible. For example, one patient with impaired vital capacity improved following successful treatment of the plasma cell disorder with Tamoxifen [26] . In another report, three patients demonstrated improvement in PFTs following aPBSCT [7] . Our study confirms both statistically and clinically significant improvements in pulmonary function tests following aPBSCT. These improvements include spirometry, lung volumes (except residual volumes), DLCO, and respiratory muscle function. It was hypothesized that the pulmonary function tests improvements may be explained by changes in edema; however, no significant changes in weight were seen following aPBSCT which makes this theory less likely (Table 2 ). However, absence of weight changes may not rule out improvements in extra-vascular volume overload. Interestingly eleven of thirteen patients did show resolution of pleural effusions following aPBSCT. Given the improvement in respiratory muscle strength, FVC and RV/ TLC it is likely that improvement in neurologic weakness accounts for some of the improvement in pulmonary function testing. Dramatic improvements in neurologic manifestations of POEMS syndrome has been reported previously following treatment with lenalidomide [27] . Neurologic weakness may also cause atelectasis which can lead to a diminished DLCO. Improvement in atelectasis associated with neurologic improvement may explain some of the improvement in DLCO. In addition, a prior study found that 96% of POEMS syndrome patients with pulmonary hypertension had an abnormal DLCO [3] . We did find that an abnormal DLCO was significantly associated with an abnormal RVSP (p Z 0.0034). Improvement in RVSP may explain some of the DLCO improvement. The TLC, MEP, and FEV 1 measurements at a median of 26.5 months following aPBSCT supported a persistent change. Interestingly DLCO, MIP and FVC at a median of 26.5 months continued to demonstrate small but statistically significant continued improvement. This finding is encouraging to patients and clinicians deciding to pursue aPBSCT for POEMS syndrome in the face of pulmonary impairment.
Pulmonary hypertension
Pulmonary hypertension is a known complication of POEMS syndrome [28e30] . In fact, our previous study demonstrated pulmonary hypertension as high as 48% in the patients screened with ECHO [1] . Prior reports have demonstrated improvement in pulmonary hypertension following treatment with steroids (intravenous or oral) with or without plasmapheresis, mycophenolate mofetil or thiamine [3, 8, 12, 13, 28, 31, 32] . Pulmonary hypertension has been proposed to be caused by elevated cytokines in POEMS syndrome [11] . Interestingly, bevacizumab (humanized monoclonal anti-VEGF antibody) improved pulmonary Figure 1 A: Chest X-ray in POEMS syndrome patient before aPBSCT. Note right-sided pleural effusion, low lung volumes, and infiltrates. B: Same patient's chest X-ray three months after aPBSCT demonstrating resolution of abnormal findings.
hypertension in a patient with POEMS syndrome and pulmonary hypertension [33, 34] . However, improvement in POEMS syndrome with bevacizumab appears to be inconsistent based on available data [35] . Our series demonstrated 58% of the POEMS syndrome patients who underwent ECHO had an elevated RVSP. Following aPBSCT patients had a statistically significant decline in RVSP. However, our analysis did not demonstrate any significant correlation between abnormal RVSP and IL-6 and VEGF levels (p Z 0.59 and p Z 0.22 respectively). Due to a small number of longer term follow-up ECHOs the trajectory of improvement in RVSP cannot be further delineated in this cohort.
Chest imaging
Abnormalities in chest imaging were common in POEMS syndrome patients but improved following aPBSCT.
aPBSCT pulmonary mortality and critical illness
It is well known that aPBSCT is accompanied by risks including respiratory failure and death. ICU and early deaths were previously demonstrated to be due to periengraftment syndrome [36] . In our study several patients required either invasive or non-invasive mechanical ventilation and there was one death as previously reported. [7] .
Cytokines
The etiology of POEMS syndrome is unclear but could be related to several cytokines produced by the plasma cells. Prior reports hypothesize that cytokines are responsible for pulmonary hypertension and other manifestations of POEMS syndrome such as edema [11, 37] . Elevated levels of VEGF and IL-6 have been reported in active POEMS syndrome with decreased levels following treatment [37e45]. In our study we found that VEGF and IL-6 levels were elevated at baseline and decreased following aPBSCT however no correlation was found between these cytokines and abnormal RVSP.
Limitations
Our study has limitations. It is a retrospective cohort study therefore timing of tests were not standardized by protocol. Due to the small number of patients with blood gas data obtained pre-transplant, change in the partial pressure of oxygen or carbon dioxide could not be analyzed in this cohort. With respect to PFTs, however, this limitation is somewhat ameliorated by the narrow time range that follow-up PFTs occurred in and the availability of most tests of interest in our patients. In addition, our study can mainly be applied to patients with mild to moderate lung disease. Only four patients had severe impairment of DLCO (DLCO <40% predicted) and only one patient had severe impairment of FEV 1 (FEV 1 <40% predicted). Further study is needed to determine if POEMS syndrome patients with severe impairment in lung function have similar recovery in lung function following aPBSCT. Further our data on pulmonary hypertension is limited because pulmonary pressure was estimated by echocardiogram not measured by right heart catheterization. This limitation is consistent with prior reports as minimal right heart catheterization data is reported in the literature with most prior reports relying on ECHO estimations [1, 3] . Finally, RVSP measurements after aPBSCT were available only for fourteen patients. Nevertheless, our study demonstrated modest and statistically significant improvement in right ventricular systolic pressure by echocardiogram.
Conclusions
In summary, patients with POEMS syndrome should be evaluated for PFT, imaging and RVSP abnormalities as such abnormalities are common in POEMS syndrome. Pulmonary morbidity in POEMS syndrome improves with aPBSCT including improvements in imaging, spirometry, TLC and RV/TLC, respiratory muscle pressures, and RVSP, but does carry risks of respiratory failure and death following transplant (which is minimized if one is attuned to and ready to treat engraftment syndrome). Once improved pulmonary function test improvements appear stable (FEV 1 , MEP, and TLC) or slightly improved (DLCO, MIP, and FVC) with long-term follow-up. Therefore, mild to moderate pulmonary function test impairments should not be considered a contraindication to aPBSCT. 
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